Efficacy of Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation
Status:
COMPLETED
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This is a single-center, parallel-group, randomized, open-label trial evaluating the effect of 3-month treatment with dapagliflozin 10mg once daily on the recurrence of atrial fibrillation after catheter ablation for atrial fibrillation in patients without diabetes, heart failure, or chronic kidney disease.